Document is current
Any future updates will be listed below
-
Authors
Perton, F. T. https://orcid.org/0000-0001-7331-0104
Bentvelzen, M. L. M. https://orcid.org/0009-0003-5054-1569
Fadaei, S. https://orcid.org/0000-0002-7507-5002
Pouw, J. N. https://orcid.org/0000-0002-1818-7833
Spierings, J. https://orcid.org/0000-0002-2546-312X
Vonkeman, H. E. https://orcid.org/0000-0003-3792-7718
Mooij, S. C. https://orcid.org/0009-0002-7517-7348
Schipper, L. G. https://orcid.org/0009-0007-6379-1240
Herman, A.
,
Bhansing, Kavish J.
Bisoendial, Radjesh J.
van Bijnen, Sandra T.A.
van Bon, Lenny
Comarniceanu, Antoaneta C.
Herman, Amin
Jahangier, Z. Nazira
Jansen, Tim L.T.A.
Kloth, Jacqueline S.L
Kok, Marc R.
van Kuijk, Arno W. R.
Leijten, Emmerik F.A.
Mooij, Shasti C.
Schipper, Lydia G.
van Tubergen, Astrid M.
Vonkeman, Harald E.
Vreugdenhil, Simone A.
Wijngaarden, Siska
Mastbergen, S. C. https://orcid.org/0000-0002-8825-6486
Welsing, P. M. J. https://orcid.org/0000-0003-2361-2803
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 17 September 2025
First Online: 27 October 2025
Declarations
:
: Reported in open protocol publication [ ].
: Not applicable.
: HEV: paid consultant for Abbvie, Novartis, Pfizer, UCB, Johnson and Johnson. Financial grants from (pharmaceutical) companies: Galapagos and Boehringer Ingelheim AWRVK: Paid consultant for Janssen, Novartis and UCB. Financial grants from Novartis and UCB.
